Background Treatment with highly active antiretroviral therapy (HAART) has improved survival in HIV patients with PML, but mortality rates in certain groups of patients remain high. We sought to identify characteristics associated with prognosis.
Methods We reviewed clinical data with particular emphasis on antiretroviral treatment history. Survival time was calculated from the time of PML diagnosis to the date of the last clinic visit or death. Survival according to HAART status was analyzed through Kaplan-Meier survival curves.
Results Forty patients met inclusion criteria for this study. Eighty-six percent had a CD4 count < 100 cells/mm3 and 52% had a prior history of AIDS-defining illness; no baseline factors were significantly associated with survival except HAART status. Fifteen patients received cidofovir in addition to HAART, but cidofovir was not associated with improved survival.
Conclusion HAART-naive patients started on HAART treatment after PML diagnosis have a significantly better prognosis.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.